Relapsed Refractory Acute Myeloid Leukemia clinical trials

Explore recruiting relapsed refractory acute myeloid leukemia clinical trials.

Recruiting relapsed refractory acute myeloid leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Acute Myeloid Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

Sweden, Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML)

Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Italy, Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A PHASE I/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MEBENDAZOLE IN COMBINATION WITH LOW-DOSE ARA-C IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (MAIL)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Relapsed Refractory Acute Myeloid Leukemia trials by city

Relapsed Refractory Acute Myeloid Leukemia in Toronto Relapsed Refractory Acute Myeloid Leukemia in Vancouver Relapsed Refractory Acute Myeloid Leukemia in Montreal Relapsed Refractory Acute Myeloid Leukemia in Calgary Relapsed Refractory Acute Myeloid Leukemia in Edmonton Relapsed Refractory Acute Myeloid Leukemia in Ottawa Relapsed Refractory Acute Myeloid Leukemia in Winnipeg Relapsed Refractory Acute Myeloid Leukemia in Quebec City Relapsed Refractory Acute Myeloid Leukemia in Hamilton Relapsed Refractory Acute Myeloid Leukemia in Kitchener Relapsed Refractory Acute Myeloid Leukemia in London Relapsed Refractory Acute Myeloid Leukemia in Halifax Relapsed Refractory Acute Myeloid Leukemia in New York Relapsed Refractory Acute Myeloid Leukemia in Los Angeles Relapsed Refractory Acute Myeloid Leukemia in Chicago Relapsed Refractory Acute Myeloid Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease